Researchers sought to describe the first 3 patients in Canada who developed vaccine-induced immune thrombotic thrombocytopenia after receiving the adenoviral vector vaccine against COVID-19.
Researchers sought to identify the experiences of patients who developed prothrombotic immune thrombocytopenia after receiving the ChAdOx1 vaccine (AZD1222) against SARS-CoV-2.
Researchers sought to describe the unexpected autoimmune prothrombotic disorder experienced after vaccination with the ChAdOx1 COVID-19 vaccine.
Researchers described outcomes for 3 patients in Canada who were treated with high-dose IVIG for vaccine-induced immune thrombotic thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine.
Researchers sought to determine the long-term safety and efficacy of fostamatinib for treating patients with immune thrombocytopenia and rheumatoid arthritis.
Researchers attempted to develop a predictive model for the risk of postpartum hemorrhage in patients who have ITP.
Researchers sought to determine whether patients with ITP treated with eltrombopag would have SROT.
Researchers attempted to revise clinically relevant definitions for patients with iTTP in light of recent changes.
A letter to the editor drew attention to the increased risk of thrombotic disorder for patients with severe COVID-19, which seems to occur by interacting with the von Willebrand Factor-ADAMTS13 axis.
A team of researchers sought to determine the frequency of and risk factors associated with ischemic stroke in patients with immune thrombotic thrombocytopenic purpura.
